Step Pharma shares early Phase II VECTRA trial data for dencatistat in essential thrombocythaemia (ET) ahead of ASH 2026.
Mondego Bio has begun first-in-human dosing of MB-388, an oral PTPN2/PTPN1 inhibitor aimed at overcoming cancer immunotherapy ...
Acepodia dosed the first patient in a Phase I trial of ACE723, a GPC3-targeted dual-payload ADC for liver cancer. Read the ...
Moderna's mRNA-2808 yields four confirmed responses in Phase I/II myeloma study targeting BCMA, GPRC5D and FcRH5. Read the ...
Cambridge spinout T-Therapeutics closes $133m Series B to advance TCR bispecifics in cancer and autoimmune disease. Read the full story for what's next.
Alethio Therapeutics raises USD 90M Series A to advance ATX-011, a G6B antibody for essential thrombocythaemia. Read the ...
Cardiol Therapeutics unveils a USD 75M at-the-market equity program after its MAVERIC Phase III trial met enrollment early.
Emvena Therapeutics launches with seed funding from the Penn-BioNTech PxB Fund to build placenta-targeted mRNA medicines.
AbbVie licenses Nxera's oral EP4 agonist NXE0033744 for IBD in a $100M upfront global deal. Read the key terms and what this ...
Pfizer Q3 2026 earnings: second positive Elrexfio Phase III readout, atirmociclib tolerability data and mevrometostat delay.
Novo Nordisk Q3'26 earnings: Neuropathic pain expansion and next-generation obesity pipeline advance
Novo Nordisk Q3 2026 earnings show CagriSema outperforming tirzepatide in weight loss. Explore the full pipeline update, ...
A2 Biotherapeutics' MSLN-targeting A2B694 CAR T therapy produced a 12-month-plus complete response in one NSCLC patient. Read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results